Ascenta breaks ground with Chinese research ops

The L.A. Times has the story of Ascenta Therapeutics, which has been tapping scientists at a facility in China to advance its drug prospects while keeping R&D budgets in line. According to the Times, the experts see Ascenta as something of a test case, blazing a trail in China that other smaller developers are likely to follow. China has some tough competition in India and Eastern Europe. That's one reason why government officials have aggressively attacked corruption at China's FDA, recently sentencing the former head of the Chinese agency to death for accepting bribes.

- here's the article from The Los Angeles Times

Related Article:
Ascenta gins $50M in third round. Report
China says former drug czar accepted bribes. Report
China's future in the biotech industry. Editorial
Bridge Pharma sees growth in China drug studies. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.